Open Federal Grants · National Institutes of Health
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
National Institutes of Health · Opportunity RFA-NS-26-001 · Award amount: see the official listing
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide piv
Eligibility text quoted from the official Grants.gov listing.
About This Opportunity
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagn …
Description from the official Grants.gov listing — read the complete notice, including any updates, on Grants.gov before applying.
More Open Grants From NIH
Browse Open Grants
By who can apply:
By agency:
By closing month:
Every grant listed here comes from Grants.gov, the official U.S. government database. Award amounts and deadlines can change — verify the details on the official listing before you apply. GrantRound is not affiliated with the U.S. government.